SEC Form 4 reporting owner

Bashan Dror

Bashan Dror has filed 3 Form 4 transactions reported between December 19, 2025 and September 3, 2026, as PRESIDENT AND CEO of Protalix BioTherapeutics, Inc..

Name as filed: Bashan Dror

Open-market buys, 24 mo
$101K
1 lines
Open-market sales, 24 mo
None
reported
Companies
1
with Form 4 filings
Latest transaction
Sep 3, 2026
transaction date

Roles and reported holdings

  • PLXProtalix BioTherapeutics, Inc.
    Dec 19, 2025 – Sep 3, 2026

    PRESIDENT AND CEO

    Held directly188,516 sh as of Dec 19, 2025 · Form 4

    24 months: $101K bought

Transaction history

All 3 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Sep 3, 2026PLXPRESIDENT AND CEOGrant or awardCode A · direct160,000—Form 4
Sep 3, 2026PLXPRESIDENT AND CEOGrant or awardCode A · direct320,000—Form 4
Dec 19, 2025PLXPRESIDENT AND CEOOpen-market purchaseCode P · direct56,000$101K@ $1.81Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.